1 Murray CJ，Lopez AD. Measuring the global burden

of disease[J]. N Engl J Med，2013，369：448-457.

2 Song B，Wang Y，Zhao X，et al. Association between

statin use and short-term outcome based on severity

of ischemic stroke：a cohort study[J]. PLoS One，2014，

9：e84389.

3 AI-Khaled M，Matthis C，Eggers J. Statin treatment

in patients with acute ischemic stroke[J]. Int J Stroke，

2014，9：597-601.

4 他汀类药物防治缺血性卒中/短暂性脑缺血发作专家

共识组. 他汀类药物防治缺血性卒中/短暂性脑缺血发

作专家共识[J]. 中国卒中杂志，2013，8：565-575.

5 Tsivgoulis G，Katsanos AH，Sharma VK，et al. Statin

pretreatment is associated with better outcomes in

large artery atherosclerotic stroke[J]. Neurology，2016，

86：1103-1111.

6 Tuttolomondo A，Di Raimondo D，Pecoraro R，et al.

Early high-dosage atorvastatin treatment improved

serum immune-inflammatory markers and functional

outcome in acute ischemic strokes classified as large

artery atherosclerotic stroke：A randomized trial[J].

Medicine (Baltimore)，2016，95：e3186.

7 Lee MJ，Bang OY，Kim SJ，et al. Role of statin in

atrial fibrillation-related stroke：an angiographic study

for collateral flow[J]. Cerebrovasc Dis，2014，37：77-84.

8 Martínez-Sánchez P，Rivera-Ordóñez C，Fuentes

B. The beneficial effect of statins treatment by stroke

subtype[J]. Eur J Neurol，2009，16：127-133.

9 脑小血管病诊治专家共识组. 2013中国脑小血管病诊

治专家共识[J]. 中华内科杂志，2013，52：893-896.

10 Weeks DL，Greer CL，Willson MN. Statin medication

use and nosocomial infection risk in the acute phase of

stroke[J]. J Stroke Cerebrovasc Dis，2016，25：2360-

2367.

11 王贵佐，张永红，谢新明，等. 他汀类药物与感染发生

率及死亡率关系的meta分析[J]．南方医科大学学报，

2014，7：988-993.

12 Fraunberger P，Gröne E，Gröne HJ，et al. Simvastatin

reduces endotoxin-induced nuclear factor kappaB

activation and mortality in guinea pigs despite

lower ing ci rculat ing low-densit y lipoprotein

cholesterol[J]. Shock，2009，32：159-163.

13 唐林云，闰福岭. 他汀类药物与卒中后感染的研究进

展[J]. 中华脑科疾病和康复，2015，5：352-354.

14 Schulz S，Lüdike H，Lierath M，et al. C-reactive

protein levels and genetic var iants of CRP as

prognostic markers for combined cardiovascular

endpoint (cardiovascular death，death from stroke，

myocardial infarction，and stroke/TIA)[J]. Cytokine，

2016，88：71-76.

15 Sukegawa H，Maekawa Y，Yuasa S，et al. Intensive

statin therapy stabilizes C-reactive protein，but not

chemokine in stable coronary artery disease treated

with an everolimus-eluting stent[J]. Coron Artery Dis，

2016，27：405-411.

16 Simões FV，de Batista PR，Botelho T，et al. Treatment

with high dose of atorvastatin reduces vascular injury

250 Chin J Stroke, Mar 2017, Vol 12, No.3

in diabetic rats[J]. Pharmacol Rep，2016，68：865-873.

17 Erdös B，Snipes JA，Tulbert CD，et al. Rosuvastatin

improves cerebrovascular function in Zucker obese

rats by inhibiting NAD(P)H oxidase-dependent

superoxide production[J]. Am J Physiol Heart Circ

Physiol，2006，290：H1264-1270.

18 Ueno Y，Yamashiro K，Tanaka Y，et al. Rosuvastatin

may stabi l ize atherosclerot ic aor t ic plaque：

transesophageal echocardiographic study in the

EPISTEME trial[J]. Atherosclerosis，2015，239：476-

482.

19 Haruta H，Hiro T，Mitsumata M，et al. Stabilization

of atherosclerotic plaque by pitavastatin in Watanabe

heritable hyperlipidemic rabbits：A serial tissuecharacterizing

intravascular ultrasound study[J]. J

Cardiol，2016，67：205-211.

20 Wang N，Tall AR. Cholesterol in platelet biogenesis

and activation[J]. Blood，2016，127：1949-1953.

21 Wang Q，Yan J，Chen X，et al. Statins：multiple

neuroprotective mechanisms in neurodegenerative

diseases[J]. Exp Neurol，2011，230：27-34.

22 Ljøstad U，Mygland Å. Autoimmune myopathy

associated with statin use[J]. Tidsskr Nor Laegeforen，

2016，136：1360-1362.

23 Latkovskis G，Saripo V，Sokolova E，et al. Pilot study

of safety and efficacy of polyprenols in combination

with coenzyme Q10 in patients with statin-induced

myopathy[J]. Medicina (Kaunas)，2016，52：171-179.

24 Ambapkar SN，Shetty N，Dwivedy A，et al. Statininduced

rhabdomyolysis in patient with renal failure

and underlying undiagnosed hypothyroidism[J].

Indian J Crit Care Med，2016，20：305-307.

25 Parker BA，Capizzi JA，Grimaldi AS，et al. Effect

of statins on skeletal muscle function[J]. Circulation，

2013，127：96-103.

26 Holbrook A，Wright M，Sung M，et al. Statinassociated

rhabdomyolysis：is there a dose-response

relationship?[J]. Can J Cardiol，2011，27：146-151.

27 Armitage J. The safety of statins in clinical practice[J].

Lancet，2007，370：1781-1790.

28 Rahal AJ，ElMallah AI，Poushuju RJ，et al. Do

statins really cause diabetes? A meta-analysis of major

randomized controlled clinical trials[J]. Saudi Med J，

2016，37：1051-1060.

29 Ridker PM，Pradhan A，MacFadyen JG，et al.

Cardiovascular benefits and diabetes risks of statin

therapy in primary prevention：an analysis from the

JUPITER trial[J]. Lancet，2012，80：565-571.

30 Prospective Studies Collaboration. Blood cholesterol

and vascular mor tality by age，sex，and blood

pressure：a meta-analysis of individual data from 61

prospective studies with 55，000 vascular deaths[J].

Lancet，2007，370：1829-1839.

31 Cholesterol Treatment Trialists (CTT) Collaboration.

Efficacy and safety of more intensive lowering of LDL

cholesterol：a meta-analysis of data from 170，000

participants in 26 randomised trials[J]. Lancet，2010，

376：1670-1681.

32 Collins R，Reith C，Emberson J，et al. Interpretation

of the evidence for the efficacy and safety of statin

therapy[J]. Lancet，2016，388：2532-2561.

33 Wang J，Chen D，Li DB，et al. Comparison of the

efficacy and safety of intensive-dose and standarddose

statin treatment for stroke prevention：A metaanalysis[

J]. Medicine (Baltimore)，2016，95：e4950.

34 Manocha D，Bansal N，Gumaste P，et al. Safety

profile of high-dose statin therapy in geriatric patients

with stroke[J]. South Med J，2013，106：658-664.